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GENERAL INTRODUCTION
   Over the past several decades, biotechnology has developed extensively and led to a
significant increase in the number of bioengineered products. The progress of these
fields has had a great impact on the therapeutic agents used to treat many diseases, such
as diabetes, etc., which are often difficult to treat with current medicines. Most of
these products are peptides and proteins, which are generally administered via the
parenteral route. However, oral administration is the most desirable route for taking
these drugs because ofease ofadministration, thus resulting in good patient compliance.
   Insulin remains the most effective drug for a diabetic patient to control their blood
glucose levels. The route for insulin delivery is restricted to subcutaneous injections,
as opposed to the oral route, due to insulin inactivation by proteolytic enzymes in the
gastrointestinal (GI) tract and low permeability through the intestinal membrane [1,2].
However, the subcutaneous injection of insulin has various disadvantages such as
hyperinsulinemia, pain, allergic reactions and low patient compliance. Another
important issue with insulin is that parenteral administration does not replicate the
normal dynamics of endogenous insulin release, resulting in a failure to achieve a
lasting glycemic control in patients [3,4]. The portal delivery ofinsulin, which mimics
endogenous insulin release, can be achieved via intestinal administration. Obviously,
from this perspective, the development of an oral delivery system providing adequate
bioavailability of insulin would revolutionize the treatment of diabetes. Moreover, it
can be anticipated that such a technique could be applied to delivery of other protein
drugs.
   To date, various strategies have been developed to try and achieve an oral insulin
1
delivery system, including co-administration with absorption enhancers [5,6] or enzyme
inhibitors [6,7], chemical modification [8], polymeric carriers [9-11], and lipid-based
carriers as liposomes [12] and solid lipid nanoparticles [13]. Nevertheless, these
approaches show low bioavailability and also some of them exhibit several negative
effects such as irritation of the intestinal mucosal membrane and impairment of the
membrane barrier. Therefore, it was essential to develop effective and reliable oral
delivery systems for this class of drugs. For such a development to succeed, oral
peptide and protein drug delivery systems should contain at least two essential
requirements. First, the system should protect the drugs from enzymatic degradation.
Second, the system should increase the drug permeability within the intestinal
membrane. A formulation that satisfies these requirements is encapsulation or
incorporation, which is the most widely used formulation strategy for peptide and
protein delivery systems. To date, various carriers have been used to develop such
drug delivery systems, however, the caniers have not shown sufficient bioavailability
when administered by the oral route.
   In Chapters 1--3, I discussed complexation hydrogel networks of poly(methacrylic
acid) grafted with poly(ethylene glycol) (P(MAA-g-EG)) for oral insulin delivery
systems. The P(MAA-g-EG) hydrogels were shown to exhibit pH-dependent swelling
behavior due to the formationldissociation of interpolymer complexes as shown in Fig.1
[14-16]. In the acidic environment of the stomach, these copolymers form
interpolymer complex due to hydrogen bonding between etheric groups of the graft
PEG chain and the acidic protons of the MAA network [14-16]. Under these
conditions, the network mesh size is significantly decreased and diffusion of insulin
through the network is prevented [14-16]. Hence, insulin loaded into the hydrogels
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Fig. I. Reversibie interpolymer complexation f decomplexation ofcomplexation polyrner hydrogels
can be protected from proteolytic degradation by gastric enzymes such as pepsin. In
the basiclneutral environment of the small intestine, the complexes immediately
dissociate due to repulsion of ionized pendant acid groups and the network's pore size
rapidly increases, leading to the release of insulin. The polymer is capable of highly
incorporating and rapidly releasing insulin in vitro I17]. Furthermore, P(MAA-g-EG)
has the ability to protect insulin from proteolytic degradation by inhibiting calcium
dependent proteases such as trypsin and alpha-chymotrypsin [16] and the polymer
shows mucoadhesive characteristics [18]. Insulin-loaded P(MAA-g-EG)
microparticles (henceforth designated as ILP) (with a molar ratio of MAA:EG=l:1 and
panicle diameters of 100 to 150 #m) successfully enhanced oral insulin absorption in
healthy and streptozotocin-induced type 1 diabetic rats, with up to 4.2 O/o bioavailability
[19]. Nevertheless, further optimization of the polymer delivery system is required to
improve clinical application. Therefore, in Chapters l and 2,Idiscussed to find an
optimal formulation for oral insulin delivery in in situ and in vivo experiments, focusing
on the panicle size and polyrner composition.
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   In Chapter 3, I focused on the mucoadhesive characteristics of complexation
hydrogels. Mucoadhesion refers to adhesion between polymer carriers and the mucosa
and is exhibited by certain polymers which become adhesive upon hydration. The
goal of mucoadhesive drug delivery systems is to increase the residence time of
therapeutic molecules at the specific sites within the GI tract for absorption of the drug
into the circulation. It is believed that complexation hydrogels have excellent
mucoadhesive characteristics because PEG tethers attached to the polymer network act
as adhesion promoters [18,20]. However, the mucoadhesive characteristics of the
P(MAA-g-EG) micropanicles in the GI tract have not been studied in vivo. Fully
understanding the mucoadhesive characteristics in the GI tract is of importance for
therapeutic application.
   In Chapter 4, I discussed novel drug delivery carrier, fusogenic liposomes (FL), to
further improve the mucosal absorption of insulin. FL are prepared by fusing
conventional liposomes with inactivated Sendai virus (SeV) particles, and can deliver
encapsulated contents directly and efficiently into the cytoplasm through membrane
fusion, with the same mechanism as SeV infection as shown in Fig. 2 [21-23]. The FL
envelope glycoproteins, hemagglutinating and neuraminidase (HN) and fusion (F)
protein, have critical roles in the process ofmembrane fusion [241. The HN protein is
involved in cell binding through attachment of the virus envelope to the cellular
receptors containing sialic acid, while F protein plays a major role in fusion of the
envelope with the cell membrane. So far, these SeV-mediated drug delivery systems
have been used to successfully introduce many kinds of macromolecules, such as DNA,
proteins, and nano-carriers, into animal cells [21-23]. However, the feasibility of
applying this fusion-mediated delivery system to the intestinal mucosal membranes has
4
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5
Chapter 1
 Mucosal insulin delivery systems based on complexation
polymer hydrogels: effect of particle size on insulin enteral
                    absorption
6
1. Introduction
   A successfu1 formulation for oral delivery of therapeutic peptide and protein drugs
would have to overcome two main barriers against the drugs: the enzymatic banier of
the GI tract and the physical barrier made of the intestinal epithelium. In order to
overcome these baniers, the multifunctional canier system, complexation hydrogels
showing high insulin incorporation effriciency, a rapid insulin release in the intestine
based on their pH-dependent complexation properties, enzyme-inhibiting effects and
mucoadhesive characteristics has been developed. Lowman et al. reported that the
insulin incorporated into P(MAA-g-EG) microparticles (diameter 100-150 pm)
successfu11y enhanced insulin oral absorption in both streptozotocin-induced diabetic
and non-diabetic rats, achieving 4.2 O/o bioavailability (relative to subcutaneous
administration) with significant hypoglycemic effects [19]. However, nevertheless,
further improvement ofthe delivery system is required for their clinical application. If
the size ofP(MAA-g-EG) microparticles is decreased, the mucoadhesiveness would be
increased due to an increase of surface area contact with the mucosa. If so, significant
quantities insulin could be released closer to the surface of intestine, which might result
in a decrease of protease attack and improved uptake of intact drug. Therefore, it was
hypothesized that smaller particle sizes of the polymer carrier could induce greater
hypoglycemic effects.
   In this chapter, the effect ofparticle size ofP(MAA-g-EG) on insulin absorption was
studied in the in situ absorption system. The mucoadhesion on the mucosal tissues
was compared among differently sized P(MAA-g-EG) microparticles to verify this
hypothesis. Additionally, insulin release profiles from differently sized microparticles
were evaluated. Furthermore, insulin absorption using the most effective
7
P(MAA-g-EG) microparticles were compared at various intestinal segments to
determine their site-specific effects. Finally, to ensure the safety of P(MAA-g-EG)
microparticles as a carrier via the oral route, intra- and inter-cellular integrity andlor
damage were examined by lactate dehydrogenase (LDH) leakage and membrane
electrical resistance (Rm) changes.
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2. Experimental section
2.1. Materials
   Methacrylic acid (MAA), dimethoxy propyl acetophenone (DMPA) and lactate
dehydrogenase reagent were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
Poly(ethylene glycol) (PEG) monomethacrylate (PEGMA, with nominal PEG molecular
weight of 1000, corresponding to 23 repeating units) and tetraethylene glycol
dimethacrylate (TEGDMA) were obtained from Polysciences (Warrington, PA, USA).
Crystalline human insulin (26.7 unitslmg) was kindly supplied by Aventis Research and
Technologies (Frankfurt, DE). All other chemicals were of analytical grade and
commercially available.
2.2. Synthesis of complexation hydrogels
   P(MAA-g-EG) microparticles were synthesized by a free-radical solution
polymerization of MAA and PEGMA with PEG of molecular weight 1000. The
monomers were mixed to yield solutions with a 1 :1 ratio ofMAA/EG in the gels. As a
crosslinking agent, TEGDMA was added in the amount of O.075 mol TEGDMA per
mole MAA. Following the complete dissolution of the monomer, nitrogen was
bubbled through the well-mixed solutions for 30 min to remove dissolved oxygen, a
free radical scavenger, which would act as an inhibitor for polymerization. The
initiator, DMPA, was added in the amount of 1 O/o weight of the monomers in a nitrogen
                                                             '
atmosphere. The reaction mixtures were pipetted between flat plates to form films of
O.9 mm thickness. The monomer films were exposed to UV light (Ultracure 1OO, Efos,
Buffalo, NY, USA) at1mW!cm2 at 365 nm and allowed to react for 30 min. The
ensuing hydrogels were rinsed for a week in deionized water to remove unreacted
9
monomer and uncrosslinked oligomer chains, then dried under vacuum and ground into
powders with diameters of Åq43 (Super-small ILP; SS-ILP), 43-89 (Small ILP; S-ILP)
and 180-230 (Large-ILP; L-ILP) pm.
2.3. Insulin incorporation
   Insulin loading was performed by equilibrium partitioning in pH 7.4
phosphate-buffered saline (PBS) as described previously [17]. Briefly, specific
amounts of crystalline human insulin were dissolved in O.1 mL of O.1 M HCI. The
insulin solution was diluted with 19.8 mL of PBS and pH was adjusted to 7.4 with O.1
mL ofO.1 M NaOH. Loading was accomplished by soaking 140 mg ofeach set ofthe
dried P(MAA-g-EG) microparticles for 2 h in the insulin solution. The microparticles
were collapsed with 20 mL of O.1 M HCI and filtered using cellulose acetatelcellulose
nitrate filter with 1 pm pores (Fisher Scientific International, Hanover Park, IL, USA).
The insulin-loaded polymers (ILP) were dried under vacuum and stored at 4 OC until use.
The amount of insulin into hydrogels was determined by HPLC. The HPLC was
composed of a pump (LC-10AS, Shimadzu Co. Ltd., Kyoto, Japan), a UV detector
(SPD-10A, Shimadzu), a system controller (SCL-10A), an auto injector (SIL-10A,
Shimadzu), an integrator (C-R3A, Shimadzu) and a GL-PACK Nucleosil 100-5C18
column (150Å~4.6 mm i.d.). The mobile phase was a mixture of acetonitril:O.1 O/o
trifluoroacetic acid:NaCl=31:69:O.58, vlvlwe/o. The flow rate was 1.0 mLlmin and UV
detection was performed at a wavelength of 220 nm. Insulin incorporation efficiency
was unaffected by the size ofILP, and reached more than 90 O/o ofthe initial amount.
2.4. In situ absorption study
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   The animal experiments in this work complied with the regulations of the
Committee on Ethics in the Care and Use of Laboratory Animals at Thomas Jefferson
and Hoshi Universities. Male Sprague-Dawley rats weighing 180-200 g fasted for 24
h prior to the experiments and were anesthetized by an i.p. injection of 50 mglkg
sodium pentobarbital. The rats were restrained in a supine position and kept at body
temperature of 37 OC using warming lamps. The jejunum, the ileum or the colon was
exposed following small midline incision carefully made in the abdomen, and each
segment (length=10 cm) was cannulated at both ends using polypropylene tubings (4
mm o.d., 2 mm i.d., Cole-Parmer Instrument, Vernon Hills, IL, USA). These were
securely ligated to prevent fluid loss and subsequently, carefu11y returned to their
original location inside the peritoneal cavity. In order to wash the intestinal content,
phosphate-buffered saline (PBS; pH 7.4) at 37 OC were singly circulated through the
cannula at 1.0 mLlmin for 20 min using a peristaltic pump (MasterFlexR tubing pumps,
Cole-Parmer Instniment). Subsequently, the segments were tightly closed following
removal of cannulation tubings; approximately O.5 mL of perfusion solutions remained
left in the segments. Rats were further left on the board at 37 OC for 1h to be
recovered from the elevated blood glucose levels due to surgical operations described
above. Following 1 h resting, pure insulin or each ILP (approximately 3 mg) with O.5
mL of PBS solution was directly administered into the loops (6 cm) made from the
pretreated segment (1O cm); the jejunal loop was made at 5 cm away from the ligament
of Treitz; the ileal loop was made at the end of the small intestine, just proximal to the
ileo-cecal junction; the colonic loop was made at the ascending colon. Insulin PBS
solution (O.5 mL) was used as a control. The dose for all samples was fixed at 25
IU/kg body weight. During the experiment, a O.2 mL blood aliquot was taken from the
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jugular vein att= O, 5, 1O, 15, 30, 60, 120, 180 and 240 min after dosing. The relative
bioavailability of the enterally administered insulin was calculated relative to the
subcutaneous (s.c.) route, using methods described by Matsuzawa et al. [25]. Briefly,
insulin solutions were prepared by dissolving an appropriate amount of crystalline
human insulin in PBS. The insulin s.c. doses were O.25, O.5, 1.0 and 2.0 IUIkg body
weight. Blood samples (O.2 mL) were collected fromjugular vein before and 5, 10, 15,
30, 60, 120, 180 and 240 min after dosing. Animals receiving s.c. insulin were given
the same surgical operation (the ileal loop) as in the intestinal administration study, in
order to set the same physical condition on the rats. Tuberculin syringes (1 mL) were
pre-heparinized in the usual fashion consisting of coating of the syringe wall through
aspiration of heparin and expelling all heparin by depressing plunger down to needle
hub. Plasma was separated by centrifugation at 13,OOO rpm for 1 min. The plasma
glucose levels were determined using HemoCueR B-glucose analyzer (HemoCue, CA,
USA). The plasma insulin levels were determined using an enzyme immunoassay
(Alpco Research, Windham, NH, USA). The total area under the insulin concentration
curve (AUC) from time O to 240 min was estimated from the sum of successive
trapezoids between each data point. The bioavailability was calculated relative to s.c.
injection as described above. The plasma peak level (C..) and the time taken to reach
the plasma peak level (T..) were determined from the plasma insulin level-time curves.
Mean residence time (MRT) was calculated by dividing AUMC by AUC, where AUMC
is the area under the first moment curve for insulin from O to 240 min point.
2.5. In vitro release study
   The formulations (1O mg) were placed into beakers containing 20 mL of PBS at 37
12
OC under constant stirring. Samples (O.1 mL) were taken at discrete intervals using
filtered syringes (pore size: 10 pm; Ishikawa Manufactory). Insulin concentration in
each sample was determined by using HPLC method described above. The fractional
release of insulin from the formulations, defined here as the ratio ofthe amount released
at any time (Mt) to the total amount released after 1 h (Mi) was calculated.
2.6. Mucoadhesion study
   The jejunal and the ileal loops from the pretreated segment following the in situ
experiments as described above were used. Following washing ofthe remaining PBS
in the loop with air, L-ILP or SS-ILP (each 30 mg) with O.5 mL of PBS was
administered to each loop and remained in the segments for1 h. Then, the loops were
washed by circulating PBS at 1.0 mLlmin for 1 min using a peristaltic pump. The
detached microparticles were collected, dried under vacuum and weighed. The
mucoadhesive capacity (O/o) was calculated as (the initial amount (30 mg) - the collected
amount) Å~ 1OO/the initial amount (30 mg)).
2.7. Biochemical evaluation of intestinal damage
   The ileal loop from the pretreated segment following the in situ experiments as
described above was used here. The ileum was treated with 20 mL ofPBS (warmed to
37 OC) and then flushed out with air. One milliliter ofPBS, 1 O/o (wlv) sodium caprate,
1 O/o (w!v) sodium glycocholate or SS-ILP (5 mg) PBS suspension was administered to
the ileum and incubated in the segments for 2 h. Then, the ileal loop was washed with
1.0 mL of PBS, and the intestinal fiuid was collected. The concentration of lactate
dehydrogenase (LDH) in the fluid was determined using a LDH-UV kit (Sigma-Aldrich
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Co., St. Louis, MO, USA).
2.8. Ileal membrane electrical resistance
   The ileal loop from the pretreated segment following the in situ experiments as
described above was used in this experiment. Following washing the ileum with
warmed 20 mL of PBS, the remaining PBS in the loop was then washed out with air.
Then, 10 mg of SS-ILP with O.5 mL of PBS was administered to the ileal loop and
remained left for 5 and 30 min. Similarly, O.5 mL of control (PBS) or 20 mM
Na2EDTA (ethylenediaminetetraacetic acid), as a positive control, was administered to
the ileal loop for 5 and 30 min. Immediately after each pretreatment, the ileal
segments were quickly opened along the mesenteric border to prepare the flat sheet
membranes. They were carefu11y washed with ice-cold calcium free Krebs-Ringer's
bicarbonate-buffered solution (pH 7.4) [26]. The solution (in mM) was composed of
125.0 NaCl, 11.1 D-glucose, 10.0 NaHC03, 5.0 KCI, 1.2 NaH2P04, and 4.2 mannitol.
The membranes were mounted in an Ussing chamber system (CEZ-9100,
Nihon-Kohden Tokyo, Tokyo, Japan) equipped with diffusion cells of 1 cm2 as the
effective area maintained at 37 OC. Apical and basal compartments were fi11ed with 5.0
mL of isotonic calcium free Krebs-Ringer's solution and stirred with oxygenation
(95 O/o 0215 O/o C02) for 20 min prior to monitoring electrophysiological parameters.
The spontaneous transmucosal potential difference (PD, mV) and the short circuit
current (Isc, AA) were recorded simultaneously at 20 min, and Rm (V) calculated by
PDIIsc, based on the Ohm's law. These were corrected by eliminating the offset
voltage between the electrodes and series fluid resistance, which was determined prior
to each experiment using the identical bathing solutions, yet in the absence of ileal
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membranes mounted in the chamber.
2.9. Statistical analysis
   The results were expressed as the mean Å} S.D. For group comparison, an analysis
of variance (ANOVA) with a one-way layout was applied. Significant differences in
the mean values were evaluated using Student's t-test. Differences were considered to
be significant when thep value was less than O.05.
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3. Results
3.1. Effect of particle size of ILP on insulin absorption from the ileum
   Figure 3 shows the effect of particle size of ILP on insulin absorption (A) and
resultant hypoglycemic effect (B). No apparent hypoglycemic response was observed
in the control group, demonstrating no insulin absorption from the ileal segments.
Similarly, L-ILP demonstrated the absence of appreciable insulin absorption from the
ileal segments although plasma glucose levels seemed to be lower than those ofcontrol.
In contrast, S- and SS-ILP significantly enhanced insulin ileal absorption. SS-ILP
showed more predominant enhancement effect on insulin absorption than that of S-ILP,
implying that the smaller size of ILP induced the bigger insulin absorption from the
ileum.
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   Table 1 summarizes pharmacokinetic parameters derived from the insulin
concentration-time profiles following in situ administration of ILPs to the ileal
segments. In this study, the relative bioavailability of insulin was calculated based on
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the s.c. injection study (Fig. 4). Plotting AUC of insulin vs. dose, there is the linear
relationship having r= O.934 (n=17, pÅqO.Ol). While there is no significant difference
in pharmacokinetic parameters between control and L-ILP, S- and SS-ILP induced the
significant increase in parameters, C.,., AUC and BA, which are related to the extent of
absorption. On the other hand, T.,. and MRT appeared to be unaffected by the
reduction ofthe size of ILP.
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 Fig. 4. Plasma insulin level versus time profiles following s.c. administration of insulin solution.
 Each data represents the mean Å} S.D. (n==4). Key: (closed square) O.25 IUIkg; (closed diamond)
 O.5 IUIkg; (closed circle) 1 .0 IUfkg; (ciosed triangle) 2.0 IUIkg.
Table 1.
Pharmacokinetic parameters derived from the plasma level vs. time profiles for insulin (25 IU/kg),
following in situ administration into ileal segments
Preparation Cmax (PUIML) Tmax (h) MRT (h) AUC (pU 'hlmL) BA (O/o)
Control
L-ILP
S-ILP
SS-ILP
  3.9 Å}4.4
  7.8 Å} 7.9
299.7 Å} 202.5 *
411.6 Å} 82.0 *
O.20 Å} O.39
O.17Å}O.28
O.08 Å} O. I2
O.14Å}O.24
O.38 Å} 4.60
O.48 Å} O.41
O.35 Å} O.20
O.76 Å}O.21
 2.5 Å} 3.3
  6.1 Å} 72
149.4 Å} 90.5 *
391 .4 Å} 263.7 *
05 Å} O.1
O.7 Å} 02
5.2 Å}2.8 *
12.8 Å} 8.3 *
Each data represents the mean Å} S.D. (n=3-4).
Cmax: the plasma peak level; T.,.: the time taken to reach the plasma peak level; AUC: the area under
the curve; BA: Relative bioavailability compared to s.c.
Significant difference from the control: pÅqO.05, *.
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3.2. Effect of particle size of ILP on insulin release profiles
   Figure 5 shows the effect of particle size of ILP on insulin release profiles. It
should be noted that these curves represent the release behavior of insulin from ILPs in
PBS because insulin was not released from ILPs in acidic condition. As shown in
Fig.5, each ILP can release insulin in the neutral condition. In addition, insulin was far
more rapidly released from SS-ILP than that from L-ILP in neutral condition.
                    120
                    100
                  eXe
                  8 8o
                  v
                  A- 60
                  }
                  N
                  } 40
                  sv
                    20
                     o
                      O' 10 20 30 40 50 60
                                   Time (min)
Fig. 5. Release profiles of insulin from P(MAA-g-EG) microparticles. Each data represents the
mean Å} S.D. (n=3-6). Key: (closed triangle) L-ILP; (closed circle) SS-ILP.
3.3. Effect of particle size of ILP on its adhesive capacity to the mucosal tissues
   Figure 6 shows the effect of particle size of P(MAA-g-EG) on the mucoadhesive
characteristics to the jejunal and ileal mucosa. It was demonstrated that more than
60 O/o of administered SS-ILP microparticles were tightly adhered to both the jejunum
and the ileum tissues following 1 h administration. Likewise, L-ILP showed a high
mucoadhesive capacity at both intestinal regions, however, the values were significantly
lower than those of SS-ILP. Similar trends were observed following 5 min
administration (data not shown).
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Fig. 6. Mucoadhesive capacities of P(MAA-g-EG) microparticles at jejunal and the ileal regions.
Each data represents the mean Å} S.D. (n=3). Key: (open column) L-ILP; (closed column) SS-ILP.
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3.4. Comparison of hypoglycemic effectS following administration of SS-ILP to
various intestinal segments
   Figure 7 shows the insulin absorption following SS-ILP administration into the ileal,
the colonic, and the rectal segments. The hypoglycemic effects induced by SS-ILP
were different at three intestinal regions. In the jejunal and colonic segments,
relatively weak hypoglycemic effects were observed following SS-ILP administration,
while SS-ILP induced the dramatic reduction of blood glucose levels in the ileal
segment.
                     = 200
.g
•.
-.
.e
-o 150
eXe
N-VTÅr2 100
$
g
EbD 5e
es
e
k
:
                       e
                        O 60 l20 180 240
                                  Time (min)
Fig. 7. Blood glucose level versus time profiles following in situ administration of SS-ILP (25
IUIkg) into various site of intestine. Each data represents the mean Å} S.D. (n=4-5). Key: (open
circle)jejunum; (closed triangle) ileum; (closed square) colon.
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3.5. Biochemical and electrophysiological characterization of the ileal membranes
following SS--ILP administration
   Table 2 shows the LDH leakage following 2 h administration of SS-ILP to the ileal
region. Lactate dehydrogenase was negligibly leaked into the ileal loop, which was
similar to the leakage seen in the control group. In contrast, the leakage was
dramatically induced by administration of typical penetration enhancers, 1.0 O/o (wlv)
sodium caprate and 1.0 O/o (wlv) sodium glycocholate. Likewise, the values for Rm
were unchanged following application of SS-ILP to the ileal region, compared to those
in the PBS-treated (control) counterparts (Table 3). This was quite contrastive to
active control, Na2EDTA-treated segment which induced significant decrease in the
values of Rm. These data suggested that the ileal membrane integrity and cellular tight
junctions remain mostly unaltered by the administration of SS-ILP.
Table 2.
Lactate dehydrogenase (LDH) leakage fo"owing application of PBS (control), SS-ILP,
sodium caprate and 1.00/o (wlv) sodium glycocholate
l.OO/, (w!v)
Preparation LDH leakage (U)
Control
SS-ILP
Sodium caprate
Sodium glycocholate
O.39 Å} O. 17
O.47 Å} O, 1 1
1.13Å}O.39 *
2.35 Å} 1.19 **
Each value represents the mean Å} S.D. (n=4-6).
Statistically significant difference from control: pÅqO.O1, ** ;pÅqO.05,*.
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Table 3.
Membrane electrical resistance
Na2EDTA into the ileal segment
(Rm) following application of PBS (control), SS-ILP and
Preparation Rm (9•cm2)
5 min 30 min
Controt
SS-ILP
Na,EDTA
42.7 Å}5.0
40.2 Å} 4.3
24.6 Å}5.2 *
42.3 Å} 2.9
36.1 Å}2.0
25.4 Å} 2.9 *
Each value represents the mean Å} S.D. (n=3-4).
Statistically significant difference from control: pÅq O.05,*.
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4. Discussion
   The copolymer hydrogel networks of poly(methacrylic acid) grafted with
poly(ethylene glycol) (P(MAA-g-EG)) is a promising class for oral carriers of insulin
[14-19]. Nevertheless, further optimization ofthe polymer delivery system is required
to improve clinical application. One of the important factors for improving insulin
absorption from the small intestine may be the particle size ofILP. Smaller size ofILP
would induce bigger hypoglycemic effects due to increased mucoadhesive capacity to
the intestinal mucosa. Therefore, the effect of particle size of ILP on the enteral
insulin absorption was investigated in the in situ loop system.
   As shown in Fig. 3, a reduction of particle size of ILP significantly increased the
hypoglycemic effect, with the diameters of Åq43 pm (SS-ILP) showing the highest BA
values (Table 1). These results suggest that the particle size of the hydrogels play a
critical role in oral insulin delivery. One of important factors is the enhancement effect
of mucoadhesion of the hydrogels. P(MAA-g-EG) exhibits excellent mucoadhesive
characteristics for delivery ofdrugs to the small intestine due to the presence ofthe graft
PEG chains which serve as adhesion promoters [18,20]. Thus, a size-dependent
particle deposition in the GI tract of rats has been suggested recently [28,29]. The
authors report that small size microparticles easily interpenetrate into the mucus layers
and increase mucoadhesive characteristics to the intestinal mucosa. The similar
phenomenon was observed in Fig. 6. The SS-ILP showed higher mucoadhesive
capacities to the intestinal mucosa than L-ILP. These results can support our
hypothesis that the smaller size of ILP may give the stronger bioadhesive competence.
In addition, particle size also affected insulin release profiles in the neutral condition,
and insulin was more rapidly released from the smaller size microparticles (Fig. 5).
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These imply that the smaller particle size can provide for near instant insulin release at
                         'the absorption site resulting in closer insulin release to the membrane epithelium and,
thereby, in an increase of the number of insulin molecules those can escape from
proteolysis in the lumen and more amount ofinsulin can be absorbed.
   Generally, when insulin solutions are administered to the small intestine, insulin is
subjected to extensive degradation by proteolytic enzymes and, thereby, insulin
absorption occurs negligibly like control group of this study. It has been shown that
insulin i,s degraded by pancreatic proteases like trypsin and chymotrypsin, which are
believed to reside in both intestinal fluids and the mucus/glycocalyx layers [1,2]. In
this study, enzymes in the former compartment could be removed by washing
pretreatment with PBS in the in situ experiments. However, the mucuslglycocalyx
layers might remain and in fact, the layers have significant roles in insulin's metabolic
loss [1,2]. Moreover, the importance of ectopeptidases contributing to the metabolic
loss ofcertain polypeptides including insulin has been reported [30,31]. Regardless of
such multi-compartment enzymatic barriers, however, the ileal insulin absorption
clearly occurred in the small intestine following the application of S•- and SS-ILP. One
possibility of the increased insulin's absorption may be associated with the reduced
proteolytic activity in the presence of the polymer. It has been already reported that
P(MAA-g-EG) microparticles may inhibit the metal-dependent enzymes via the binding
                                                                    'of Ca2' with carboxylic group on the backbone chain [16]. Indeed, a range of
proteases can be inhibited by chelating essential metal ions from the enzyme structure,
resulting in protein denaturation and loss of activity [32]. Therefore, this may play the
crucial role for the enhancing absorption of insulin following ILP administration.
   The SS-ILP's enhancement effect of insulin mucosal absorption showed a
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site-specificity, demonstrating maximum effect at the ileal segment (Fig.7). The
possible explanation of the results is due to the difference in proteolytic activity in the
intestine. Comparing the pancreatic enzyme activity, it was much stronger in the upper
small intestine than in the descending small intestine like the ileal segments [33].
Assuming that amount of released insulin from SS-ILP at each region would be the
same, indeed, pH value in the intestinal fluid is thought to be enough for SS-ILP
swelling, the degree of insulin degradation was much larger in the jejunum than in the
ileum. As a consequence, the net insulin amount capable of being absorbed through
the small intestine is much smaller in the jejunum than in the ileum and, therefore, it
was likely that SS-ILP administration to the jejunal segment revealed small
hypoglycemic effect. On the other hand, SS-ILP administration to the colonic segment,
where the proteolytic activity may be much smaller than those in the small intestine,
induced little or no hypoglycemic effects. The result is presumably due to the
thickness ofmucus layers [34] and tightness oftightjunctions ofthe colon [35]. It is
well known that the presence ofthe mucus layers was one of the pemieation baniers for
peptide and protein drug absorption [36-38]. It was demonstrated that the
diminishment of mucus/glycocalyx layers showed the significant increase of insulin
permeability [1,2]. Furthermore, the tight junction is more rigid in the large intestine
than in the small intestine, so the permeability of macromolecular drugs from the large
intestine might be lowered compared with the small intestine [35]. Although PEG
chain grafted in PMAA was penetrated into mucus layers [18,20], and P(MAA-g-EG)
may be adhered to the mucosal membrane, because of having thicker mucus layers and
tightness of mucosal membrane in the colonic region, insulin absorption in the colon
may be decreased, even though the insulin was released to the same extent in the
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colonic segment as in the small intestine. These results suggest the necessity for oral
P(MAA•-g-EG) microparticles to be delivered into the lower small intestine to attain
higher insulin absorption.
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5. Conclusions
   Smaller sized P(MAA-g-EG) microparticles (SS-ILP) showed the higher insulin
absorption compared with the microparticles having larger size (L-ILP), resulting in
greater hypoglycemic effects without detectable mucosal damage such as LDH leakage
and Rm reduction. Furthermore, SS-ILP demonstrated higher mucoadhesive capacity
to the jejunum and the ileum than those of L-ILP. The high mucoadhesive capacity
may reduce insulin degradation in the mucus!glycocalyx layers, thereby increasing
insulin absorption from the small intestine. A rapid burst-type release of insulin was
observed with the smaller sized ILP which was believed to have contributed to an
increased relative bioavailability of insulin. Moreover, SS-ILP's enhancement effect
of insulin mucosal absorption showed a site-specificity, demonstrating maximum effect
at the ileal segment. These results imply that the use of smaller size of P(MAA-g-EG)
microparticles, and the delivery of them to the lower small intestine holds promise for
increasing the bioavailability of insulin following oral administration.
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Chapter 2
Oral insulin delivery systems based on complexation polymer
 hydrogels: Single and multiple administration studies in
              type 1 and 2 diabetic rats
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1. Introduction
   As shown in Chapter 1, ILP enhanced enteral insulin absorption with significant
hypoglycemic effects without detectable mucosal damage. Recent in vitro studies
suggest that the molar ratio of MAA:EG is an important parameter as it affects the
insulin release behavior from microparticles, the ability of the carrier to protect insulin
from enzymes, and the adhesive characteristics on the mucus membrane [17]. In
addition, in situ absorption study described in Chapter 1 showed that the ILP particle
size influenced strongly the intestinal insulin absorption with the smaller ILP size
greatly enhancing insulin absorption, leading to a 12.8 O/o relative bioavailability.
Based on observations obtained from the in vitro and in situ experiments, this chapter
aimed to identify an optimal formulation and prove the ability of the prepared particles
to act as carriers for oral insulin delivery in in vivo experiments. The most promising
formulation would be used for in vivo single and multiple oral administration studies
using type 1 and 2 diabetic rats.
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2. Experimental section
2.1 Materials
   MAA, DMPA, TEGDMA, and PEGMA were the same as described in Materials of
Chapter 1. Streptozotocin was obtained from Sigma-Aldrich Co. (St. Louis, MO,
USA). Crystalline recombinant human insulin (26.0 unitslmg) was obtained from
Wako Pure Chemical Industries Co., Ltd (Osaka, Japan). All other chemicals were of
reagent grade and were used without further purification.
2.2 Synthesis of complexation hydrogels
   Complexation hydrogels were synthesized by the same method as described in
Synthesis of complexation hydrogels of Chapter 1. In this chapter, we prepared three
different molar ratio of complexation hydrogels with 1:O, 4:1 and 1:1 mm:EG units.
In addition, particles size was adjusted with diameters of Åq53 (SS size) and 212-300 (L
size) pm.
2.3 Insulin incorporation
  Insulin incorporation was the sameas described in Insulin incorporation of Chapter 1 .
2.4 In vivo absorption study
   This research complied with the regulations of the Committee on Ethics in the Care
and Use of Laboratory Animals of Hoshi University. Male Wistar rats (180-200 g)
were purchased from Sankyo Lab Service Co., Ltd. (Tokyo, Japan). Animals were
housed in rooms controlled at 23Å}1 OC and 55Å}5 O/o relative humidity and allowed free
access to water and food during acclimatization. Type 1 diabetes was induced by
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intravenous injection of streptozotocin (55 mg/kg body weight) dissolved in a citrate
buffer at pH 4.5. Three days after strepotozotocin treatment, the rats with a fasted
blood glucose level År250 mgldL were selected as type 1 diabetic rats. As a
spontaneous model for type 2 diabetes [39], Goto-Kakizaki (GK) rats were used
because GK rats display malfunctional insulin secretion against glucose and mild
hyperglycaemia. GK rats were purchased from Sankyo Lab Service Co., Ltd. (Tokyo,
Japan). The average pre-dose blood glucose levels of the healthy, type 1 and type 2
diabetic rats used in this study were 99Å}2, 319Å}6 and 149Å}4 mgldL (mean Å} SD,
n==25-45), respectively. During the experimental period, rats were housed in cages and
given water ad libutum. Rats were restrained in a supine position on a board during
administration and blood sampling. Gelatin capsules (Qualicaps@ capsule, Shionogi
Quolicaps Co., Ltd, Nara, Japan) containing ILP (approximately 1, 3, and 6 mg at the
insulin doses 10, 25, and 50 IUIkg, respectively) or insulin solutions were orally
administered using a sonde needle.
   In a single administration study in healthy rats, the insulin doses were 1O, 25, and 50
IUIkg. In the case oftype 1 and 2 diabetic rats, one insulin dose of25 IUIkg was used.
In order to calculate the efficacy of oral insulin administration relative to subcutaneous
insulin, insulin solutions (1.0 IUIkg) were administered subcutaneously to healthy rats.
Insulin solutions were prepared by dissolving an appropriate amount of crystalline
human insulin in PBS. Rats were fasted for 48 h prior to the experiment. During the
experiment, a O.2 mL aliquot ofblood was collected from thejugular vein at O.25, O.5, 1,
2, 4, 6, and 8 h following dosing.
   In the multiple administration study, type 1 and 2 diabetic rats were fasted for 12 h
prior to the study, and administered ILPs 3 times lday. Each insulin dose was fixed at
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25 IUIkg. In the case of the multiple administration study, ILP (25 IUIkg) was also
administered in combination with subcutaneous insulin (O.1 IUIkg), but only at the first
dosing. The diabetic rats were fed for 30 min, 30 min after each drug administration
and allowed free access to water. The hypoglycemic effects ofSS-ILP were influenced
by the fasting period of rats. Although the hypoglycemic effects were decreased by
shortening the fasting period, suffTicient insulin's effects were observed following oral
administration ofSS-ILP to the non-fasted rats (data not shown). These results suggest
that SS-ILP may have the ability to reduce the blood glucose levels sufficiently under a
feeding condition. In this study, therefore, the diabetic rats were fed for 30 min after
each drug administration in the multiple oral administration study.
   After blood sampling, the plasma was separated by centrifugation at 13,OOO rpm for
1 min and kept at 4 OC until insulin concentration analysis. The plasma insulin
concentrations were determined on the same day as the absorption study by an
immuno-chemiluminometric assay (MLT research limited, Wales, UK) using a
microplate luminometer (Mithras LB940, Beltold Japan Co., Ltd., Osaka, Japan).
Blood glucose levels were determined using a glucose meter (Novo Assist Plus, Novo
Nordisk Pharma Ltd., Tokyo, Japan). Post-dose blood glucose levels were expressed
as a percentage of pre-dose blood glucose levels.
   The extent of hypoglycemic response was calculated as the area above the blood
glucose level-time curve below the 100 O/o line ([AAC]p... and [AAC]s.c. (O/o glu.reduc.'h)
for oral and subcutaneous insulin to healthy rats, respectively) for O-8 h. The relative
pharmacological availability (PA(O/o)) of the orally administered insulin was calculated
according to Eq. (1) in which [AAC],.,. was determined after subcutaneous
administration of 1 .0 IUIkg of insulin.
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PA(O/o)
=
 ([AAC]p.o.ldosep.o.) Å~ 1OOI([AAC],.c.ldoses.c.) (1)
2.5 Statistical analysis
   The results were expressed as the mean Å} SE. For group comparison, an analysis
of variance (ANOVA) with a one-way layout was applied. Significant differences in
mean values were evaluated by a Student's t-test. A difference was considered to be
statistically significant when thep value was less than O.05.
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3. Results
3.1 Influence of the MAA/EG molar composition of the carrier hydrogel on oral
insulin absorption
   Figure 8 shows the blood glucose levels versus time profiles following oral
administration of ILPs (Åq53 pm) with different molar ratios of EG to MAA at an insulin
dose of 25 IUIkg to healthy rats. First, it is clear that no hypoglycemic effect was
observed during administration of pure insulin solution, demonstrating the well known
absence of insulin absorption via the oral route in the absence of a suitable canier.
Rather, blood glucose levels rapidly increased due to the physical stress during oral
administration and blood sampling. Over the course ofthe study period, blood glucose
levels did not return to the initial levels. However, the oral administration of insulin
loaded microparticles prepared with a 1:1 molar ratio ofMAAIEG units suppressed the
initial rise in blood glucose levels as compared with other formulations. In addition,
the blood glucose levels of the rats decreased remarkably, achieving a maximum
hypoglycemic effect at 4 h, and with effects continuing up to 8 h. In the case of the
microparticles prepared from 4:1 and 1:O molar ratios of MAAIEq a stress-induced
increase in blood glucose levels occurred, as with the insulin solution, and there were no
significant differences in blood glucose level-time profiles between control and both
microparticle groups.
   Figure 9 shows insulin and blood glucose level-time profiles following
subcutaneous injection of an insulin solution to healthy rats at a dose of 1.0 IUIkg.
Table 4 shows the values of the hypoglycemic response, the AAC, and the PA of each
formulation calculated from the comparison of the AAC values to that of s.c. injection.
The AAC values of insulin s.c. injection at a dose of 1.0 IUIkg was 57.6Å}9.5 O/o
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glu.reduc.•h. While there is no significant improvement of the values of PA in the in
vivo studies with administration of pure insulin solution, or insulin-loaded
microparticles prepared from 1 :O and 4:1 molar ratios of MAAIEq a remarkably higher
PA was observed when using formulations based on ILPs with a 1:1 molar ratio of
MAAIEG.
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 Fig. 8. Changes in blood glucose level versus time profiles following oral administration of ILP (25
 IUfkg) containing different ratios of MAA:EG in healthy male Wistar rats. Each value represents
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Table 4.
Pharmacological
Wistar rats
availability of insulin solution and various ILPs administered orally to
Preparation
    AAC
(O/o glu. reduc. ' h)
PA
(e/o)
Insulin solution
P(MAA-g-EG) microparticle
      MAA:EG= 1 :O
      MAA:EG=4:1
      MAA:EG-1:1
1.3 Å}O.8
 2.8Å}l.7
 2.5Å}l.9
106.1 Å} 47.3 **
o.o Å} o.o
O.2 Å} O.1
02 Å} O.1
7.4 Å}3.3 **
           a AAC denotes area above the curve.
           b PA denotes pharmacological availability.
           Each value represents the mean Å} S.E.
           Statistically significant difference from insulin solution: pÅqO.O1, *".
3.2 Infiuence of ILP particle size on oral insulin absorption
   Figure 10 shows the insulin and blood glucose level profiles following oral
administration ofthe 1:1 molar ratio of MAAIEG microparticles with diameters ofÅq53
(SS-ILP) and 212-300 (L-ILP) pm and with an insulin dose of25 IUIkg. The L-ILP
samples did not induce any hypoglycemic effects and their profiles were close to those
observed in the control group. In contrast, the SS-ILP induced insulin absorption from
the GI tract, and resulted in significant hypoglycemic effects. This observation was
consistent with the results ofChapter 1.
   A dose-dependent insulin study was performed and the PA values following oral
administration ofILPs at doses of 10, 25 and 50 IUIkg are summarized in Table 5. No
pharmacological responses were observed following administration of an insulin
solution even at the highest dose, 50 IUIkg. On the other hand, the ILPs exhibited
higher PA values. Although the PA values ofILPs decreased as insulin doses increased,
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the PA values were greater in SS-ILPs than L-ILPs at all insulin doses.
SS-ILP formulation was selected as the most promising one and used
single and multiple administration studies using diabetic rats.
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Fig. 10. Changes in plasma insulin (open symbol) and blood glucose level (closed symbol) versus
time profiles following oral administration ofdifferent particle size ofILP (25 IU/kg) in healthy male
Wistar rats. Each value represents the mean Å} S.E. (n=6-12). Statistically significant difference
from control: pÅqO.Ol,*"; pÅqO.05,*. Key: (square) insulin solution (control); (triangle) L-ILP;
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    Table 5.
    Pharrnacological availability of insulin solution and various ILPs administered orally
    to Wistar rats
 Dose
(IUIkg)
Preparation
    AAC
(O/o glu. reduc.' h)
PA
(o/o)
10
25
50
Insulin solution
   L-ILP
   SS-ILP
Insulin solution
   L-ILP
   SS-ILP
Insulin solution
   L-ILP
   SS-ILP
    o.7Å}O•6 1
*[l2.-gll6,Igl'*
    1.3Å}O.8 1
*[,,g17, l2;, 1'*
    1.7Å}1.2 1
,[ ]fl3, l. ?69, 1"'
   o.o Å} o.o
   3.3 Å} 2.9
*[
   9.5 Å} 2.0
   o.o Å} o.o
   O.3 Å} O.2
*[
   7.4 Å} 3.3
   o.o Å} o.o
   O.5 Å} O.3*[
   1.8 Å} O.3
]**
]**
]**
a AAC denotes area above the curve.
b
 PA denotes pharmacological availability
Each value represents the mean Å} S.E.
Statistically significant difference between the preparation: pÅqO.O1,
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** ;pÅqO.05, *.
3.3 Hypoglycemic effects following the single oral administration of SS-ILP to
diabetic rats
   Figure 11 shows the hypoglycemic effect following a single oral administration of
SS-ILP to diabetic type 1 and 2 rats at a dose of25 IUIkg. The oral administration of
an insulin solution to type 1 and 2 diabetic rats did not decrease the blood glucose levels,
however, a significant glucose reduction was observed in both diabetic rat groups
following oral administration of SS-ILP. The strong hypoglycemic effect was
observed during the entire study period in both rat groups and blood glucose levels did
not retum to the initial levels. These observations clearly demonstrate that the SS-ILP
is an effective formulation for oral insulin delivery to diabetic rats, irrespective of the
diabetes type.
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Fig. 1 1. Changes in blood glucose level versus time profiles following oral administration of SS-ILP
(25 IUfkg) in (A) type 1 and (B) type 2 diabetic rats. Each value represents the mean Å} S.E. (n =5).
Statistically significant difference from control: pÅqO.Ol,"*; pÅqO.05,*. Key: (open circle) insulin
solution (control); (closed circle) SS-ILP.
3.4 Hypoglycemic effects following the multiple oral administration of SS-ILP to
diabetic rats
   In order to ensure the usefulness of the SS-ILP formulations, a multiple oral dosing
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 study was carried out, as would be needed for a diabetes regimen. The SS-ILP was
 administered 3 timeslday to type 1 and 2 diabetic rats. Figure 12 shows the blood
 glucose level-time profiles following multiple oral administration of SS-ILP to type 1
 diabetic rats. As shown in Fig. 12, SS-ILP significantly suppressed the postprandial
 rise in blood glucose and showed continuous hypoglycemic effects. In addition, the
 blood glucose levels prior to each meal could be kept almost the same as the pre-dose
 values. These results suggest that the multiple oral administration of SS-ILP was
 highly effective for controlling the glucose level after meals. In contrast, in the
 insulin solution administration group, glucose levels increased after the meal and did
 not return to the initial values. Therefore, the pre-dose value prior to the second and
 the third oral administration of insulin solution was substantially higher than the
 baseline values.
   In the type 2 diabetic rats group, the overall blood glucose levels tended to fluctuate
more than those observed in the streptozotocin-induced type 1 diabetic rats group (Fig.
13). However, SS-ILP significantly suppressed the postprandial rise in blood glucose
levels in the type 2 diabetic rats group, similarly to the type 1 diabetic rats group.
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 Fig. 12. Changes in blood glucose level versus time profiles in type 1 diabetic rats following
 multiple oral administration of SS-ILP (25 IUfkg). Each value represents the mean Å} S.E.
 (n=5-10). Statistically significant difference from control: pÅqO•Ol,"*; pÅqO.05,*. Key: (open
 circle) insulin solution (control); (closed circle) SS-ILP.
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  Fig. 13. Changes in blood glucose level versus time profiles in type 2 diabetic rats following
  multiple oral administration of SS-ILP (25 IUfkg). Each value represents the mean Å} S.E.
  (n=5-10). Statistically significant difference from control: pÅqO.Ol,""; pÅqO.05,*. Key: (open
  circle) insulin solution (control); (closed circle) SS-ILP.
   As shown in Fig. 12, multiple oral administration of SS-ILP caused a significant
decrease of glucose levels compared with control, however the glucose Ievels at 24 h
after administration were slightly higher than the baseline levels. Therefore, in order
to avoid increasing the pre-dose glucose levels, an insulin s.c. injection was
administered to type 1 diabetic rats together with the oral SS-ILP at the first dosing (Fig.
14). As shown in Fig. 14, co-administration of oral ILP and an insulin s.c. injection
strongly suppressed the initial rises of glucose levels after the first meal. In addition,
throughout the study period, blood glucose levels could be kept low by only one s.c.
injection along with multiple oral SS-ILP administrations.
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Fig.14. Changes in blood glucose level versus time profiles in type 1 diabetic rats following
multiple oral administration of SS-ILP (25 IUfkg) and subcutaneous insulin solution (O.1 IU!kg,
only at the first dosing). Each value represents the mean Å} S.E. (n=5-10). Statistically
significant difference from control: pÅqO.Ol,"*; pÅqO.05,*. Key: (open circle) oral administration
of insulin solution (control); (closed circle) subcutaneous administration of insulin solution; (open
square) SS-ILP and subcutaneous insulin solution.
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4. Discussion
   To date, various polymeric carriers have been used to develop peptides and protein
drug delivery systems, however, the caniers have not shown sufficient bioavailability
when administered by the oral route. In the case of insulin, an oral delivery system
which can successfully control blood glucose levels following multiple oral
administrations under feeding conditions has not yet been reported. In this chapter, I
attempted to identify the optimal formulation of ILP and to prove their potential as an
oral insulin canier in the in vivo absorption study.
   As shown in Fig. 8, an increase of the EG molar ratio of P(MAA-g-EG)
significantly increased the hypoglycemic effect, with administration using the 1:1 molar
ratio microparticles of MAAIEG showing the highest PA values (Table 4). These
results suggest that the PEG chains in the hydrogels play a critical role in oral insulin
delivery. Polyethylene glycol chains are the essential component for exhibiting
pH-dependent swelling, since the interpolymer complexes are formed by hydrogen
bonding between the carboxylic acid on MAA and the ether group on grafted PEG
chains. Lowman et al. reported that PEG chains strongly influence the mesh size of
the hydrogel networks [14]. As the EG molar ratio increased, the mesh size
significantly decreased. Therefore, an increase in the EG molar ratio provided a
network having a small enough mesh size to limit insulin diffusion in low pH
environments, while in neutral pH environments it provided a large enough mesh size
for insulin to diffuse in and out of the network. In fact, both 4:1 and 1:O ratios of
MAAIEG microparticles released more than 50 O/o of incorporated insulin in the acidic
environment [17], thereby large amount of insulin may then be degraded by proteolytic
enzymes in the stomach in this study. In contrast, a 1:1 ratio of MAAIEG
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microparticles strongly suppressed insulin release in the acidic environment, which
avoided the proteolytic degradation of insulin in the stomach. Insulin could then
rapidly be released in the small intestine. This resulted in higher PA values ofthe 1:1
ratio of MAAIEG microparticles.
   Another important factor ofPEG chains is the enhancement effect of mucoadhesion
of the hydrogels. It was reported that the tethered PEG chains enhanced adhesion to
the mucus layers due to interdiffusion and entanglements with mucus layers [18,20].
Therefore, the mucoadhesive effects of a 1 :1 ratio of MAAIEG microparticles would be
stronger than that of a 1:O or 4:1 ratio of MAAIEG microparticles. Generally, insulin
degradation by pancreatic proteases, such as trypsin and chymotrypsin, occurs in both
intestinal fluid and the mucus/glycocalyx layers [1,2]. Therefore, interpenetration of
ILP into the mucuslglycocalyx layers might lead to a reduction in proteolytic
degradation because insulin is released more closely to the surface of the intestinal
epithelial cells.
   The bioadhesive capacity of the polymer would also be dependent on particle size.
Therefore, it was hypothesized that a smaller size of ILP would cause a greater
hypoglycemic effect as compared with larger sized ILPs. As shown in Chapter 1, the
SS-ILP, having a particle size less than 53 pm, showed higher mucoadhesion than L-ILP
having a particle size between 180-230 pm. In addition, insulin was more rapidly
released from SS-ILP than from L-ILP. This implies that the smaller particle size can
provide near instant insulin release at the absorption site resulting in a higher local
concentration, thereby allowing more insulin absorption. This greatly contributes to
the high PA values of SS-ILP in single oral administration studies. The strong
hypoglycemic effects of SS-ILP were also demonstrated in a multiple oral
                                  43
administration study. In fact, this is the first demonstration that oral insulin decreases
blood glucose concentration following multiple oral administrations in the presence of
food.
   Another factor affecting the insulin absorption is the dosing amount of L- and
SS-ILP. As shown in Table 5, the PA values following oral administration decreased
with an increase in insulin dose, and the highest PA values were obtained at a dose of 1O
IUIkg following oral administration of L- and SS-ILP. In this study, insulin dose was
adjusted by the amount of ILP. Therefore, rats were administered more amount ofthe
polymer at higher insulin dose. Since the volume of releasing medium strongly
influenced the insulin release amount from the microparticles [40], the small intestinal
fluid volume might not be enough for completely releasing insulin at higher dose.
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5. Conclusions
   This study clearly demonstrated that the oral application of SS-ILP in healthy and
type 1 and 2 diabetic rats caused significant hypoglycemic effects. In a multiple
administration study, SS-ILP significantly suppressed the postprandial rise in blood
glucose and showed continuous hypoglycemic effects following 3 timeslday oral
administration to both diabetic rats groups in the presence of foods. These findings
suggest that blood glucose levels of diabetic rats can be effectively controlled by oral
SS-ILP administration, and complexation polymer hydrogels may be useful caniers for
the oral delivery ofpeptides and proteins, specially insulin.
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Chapter3
Gastrointestinal transit and mucoadhesive characteristics
        of complexation hydrogels in rats
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1. Introduction
   As described in Chapter 1 and 2, the polymer composition and particle size of ILP
strongly influenced the oral insulin absorption. In addition, microparticles of
diameters ofÅq53 pm (SS-ILP) composed ofa 1:1 molar ratio ofMAAIEG units showed
the most pronounced hypoglycemic effects following oral administration to healthy rats,
achieving a 9.50/o pharmacological availability compared to subcutaneous insulin
mJectlon .
   One of the most important attributes of the complexation hydrogels used as vehicles
for oral delivery is their ability to adhere to the intestinal mucosa and prolong the
residence time ofthe drug at the site ofabsorption. It is believed that in these systems,
PEG tethers attached to the polymer network act as adhesion promoters to enhance the
mucoadhesive behavior of the caniers [18,20]. Favorable interactions of the pendent
PEG chains in the polymer networks with the intestinal mucosa may increase the
residence time of the carriers in the GI tract. In addition, it was reported that the
particle size affected the mucoadhesive properties [28,29]. Thus, smaller size particles
tended to adhere more highly to mucus layers than did larger particles [28,29].
However, the mucoadhesive characteristics of the P(MAA-g-EG) microparticles in the
GI tract have not been studied in vivo. Therefore, the objective of this study was to
evaluate the GI transit and mucoadhesive properties of the complexation hydrogels in
rats. Particularly, we examined the influence of molar ratio and particle size of the
P(MAA-g-EG) hydrogels on the GI transit profiles and mucoadhesive characteristics.
In addition, GI transit profiles and mucoadhesive characteristics of P(MAA-g-EG)
microparticles was compared with that ofpolystyrene microparticles as an non-adhesive
particles.
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2. Experimental section
2.1 Materials
   MAA, TEGDMA, and PEGMA were the same as described in Materials of Chapter
1 and 2. PolyFluor@ 407, 9-anthracenmethyl methacrylate, and polystyrene yellow
green microparticle (45 pm) were purchased from Polysciences Inc. (Warrington, PA,
USA). 1-Hydroxycyclohexyl phenyl ketone (Irgacure@-184) was obtained from
Ciba-Geigy Co. (Hawthorne, NY, USA). Sodium deoxycholate was purchased from
Wako Pure Chemical Industries Co., Ltd (Osaka, Japan). All other chemical used were
ofreagent grade without further purification.
2.2 Preparation of fluorescently labeled P(MAA-g-EG) microparticles
   Fluorescently labeled microparticles were prepared by incorporating PolyFluor@ 407
and a fluorescent monomer into the polymer network during the polymerization reaction.
Polymer films were prepared by UV-initiated free radical solution polymerization of
MAA and PEGMA. The monomers were mixed in appropriate molar ratios to yield
solutions with 1:O and 1:1 ratios of MAAIEG in the gels, henceforth designated as
P(MAA-g-EG)(1:O) and P(MAA-g-EG)(1:1), respectively. The fluorescent monomer
was added in O.1 molO/o ofthe total monomer. TEGDMA was used as the crosslinking
agent and was added in the amount of O.75 molO/o of the total amount of monomers.
The photoinitiator, Irgacure@-184 was added in the amount of O.1 wtO/o of the total
amount of monomers. To inhibit autoacceleration in the polymerization reaction,
monomer mixture was diluted with a mixture of 50 vlvO/o ethanol and deionized water.
Nitrogen was bubbled through the well-mixed solutions for 25 min to remove dissolved
oxygen, which could act as a free radical scavenger. The reaction mixtures were
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pipetted between glass plates separated by Tefion spacers of O.9 mm thickness and
exposed to UV light (16 mWlcm2 at 365 nm) under nitrogen environment for 30 min.
The ensuing hydrogel films were removed and rinsed for 7 days in deionized water to
remove the unreacted monomers and sol fraction. Then, the copolymers were dried u
nder vacuum and crushed and sieved to powders with diameters of Åq53 (SS size) and
150-212 (L size)pm.
2.3 GI transit study
   Animal research studies complied with the regulations of the Committee on Ethics
in the Care and Use of Laboratory Animals of Hoshi University. Male Wistar rats
(180-220 g) were purchased from Sankyo Lab Service Co., Ltd. (Tokyo, Japan).
Animals were housed in rooms controlled at 23Å}1 OC and 55Å}5 O/o relative humidity and
allowed free access to water and food during acclimatization. Rats were fasted for 48
h prior to the experiment. During the experimental period, rats were housed in cages
and given water ad libutum. Rats were restrained in a supine position on a board
during administration. Gelatin capsules (Qualicaps@ capsule, Shionogi Quolicaps Co.,
Ltd, Nara, Japan) containing 10 mg microparticles were orally administered using a
sonde needle. At O.5, 1, 2, and 4 h following administration, the rats were sacrificed
by sodium pentobarbital overdose, and the stomach and small intestine (divided into
three segments) were removed. Each segment was opened lengthwise and the mucus
was scraped carefu11y away using a spatula. The mucus was dissolved in O.Ol wlvO/o
sodium deoxycholate solution. The fluorescence associated with microparticles was
measured by a fluorescence spectrophotometer (Mithras LB940, Beltold Japan Co., Ltd.,
Osaka, Japan) at excitation and emission wavelength of 355 nm and 410 nm
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(P(MAA-g-EG) microparticles),
respectively.
and 485 nm and 535 mn(polystyrene microparticles),
2.4 Transit parameters
   The transit of microparticles though the GI tract was evaluated using the kinetic
model designed by Akiyama et al. [41], and modified by Sakuma et al. [42]. It was
assumed that microparticles were emptied from the stomach and moved through small
intestine with first-order kinetics. The gastric emptying rate constant, ki, was defined
as the terminal elimination rate of the particles from the stomach to the small intestine.
The intestinal emptying rate constant, k2, was defined as the terminal elimination rate of
the particles from the intestine to the large intestine. Each rate constant was calculated
according to the following equation using the non-linear least-squares method with a
weight of 1 (MULTI) [43].
     Rs = 100 Å~ e 'kit
           100 Å~ k
                 l (e 'k2t-e-kit)
     Rsi :
            kl - k2
Where Rs is the O/o of the microparticles remaining in the stomach, and Rsi is the O/o of
the microparticles remaining in the small intestine.
2.5 Mucoadhesion study
   Male Wistar rats weighting 180-220 g fasted for 24 h were anaesthetized by an i.p.
injection of sodium pentobarbital. The rats were restrained in a supine position on the
thermostatically controlled board at 37 OC and kept at body temperature. The
duodenum was exposed following small midline incision carefu11y made in the
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abdomen, and this segment (10 cm) was cannulated at both ends using polypropylene
tubings (4 mm o.d., 2 mm i.d., Saint-Gobain Norton Co., Ltd., Nagano, Japan). These
were securely ligated to prevent fluid loss and subsequently, carefu11y returned to their
original location inside the peritoneal cavity. In order to wash the intestinal content,
phosphate-buffered saline (PBS; pH 7.4) warmed at 37 OC were circulated through the
cannula at 5 mLlmin for 4 min using peristaltic pump (PSK-51, Nikkiso Co., Ltd.,
Tokyo, Japan). Following 1 h resting, 10 mg ofmicroparticles dispersed with 1 mL of
PBS solution was directly administered into the loops. At 5 min after administration,
PBS at 37 OC was perfused for 10 min at 1 mLlmin and the amount ofmicroparticles in
the perfusate was calculated by a fluorescence spectrophotometer. Mucoadhesive O/o
was calculated using the following equation.
Mucoadhesive O/o=(dosing amount-amount ofunadhered panicle)Å~1OOIdosing amount
2.6 Statistical analysis
   The results were expressed as the mean Å} S.E. For group comparison, an analysis
ofvariance (ANOVA) with a one-way layout was applied. Significant differences in
mean values were evaluated by the Student's t-test. A difference was considered to be
statistically significant whenp value was less than O.05.
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3. Results
3.1 Distribution ofP(MAA-g-EG) micropanicles in GI tract
   The GI transit of the P(MAA-g-EG) microparticles in rats was evaluated and•
compared with that ofpolystyrene microparticles as a control. Figures 15 (A) and (B)
shows the distribution profiles of polystyrene and SS size of P(MAA-g-EG)(1:1)
microparticles in the GI tract of the rats, respectively, at O.5, 1, 2, and 4 h following oral
administration of gelatin capsules containing 10 mg microparticles. After O.5 h, the
P(MAA-g-EG)(1:1) microparticles were mostly located in the stomach, while 30 O/o of
polystyrene microparticles passed though the stomach. After 1 h, more than 60 O/o of
P(MAA-g-EG)(1:1) microparticles had accumulated in the middle and lower segments
of the small intestine. As shown in Table 6, more than 90 O/o of P(MAA-g-EG)(1:1)
microparticles existed in the whole GI tract. On the other hand, polystyrene
micropanicles immediately passed through the middle and the lower part of small
intestine, and reached at the colon. Even at 4 h, 25 O/o of the P(MAA-g-EG)(1:1)
micropaticles still located in the GI tract, whereas only 5 O/o of polystyrene
microparticles were in the same region. These results are a strong indication that the
P(MAA-g-EG)(1:1) microparticles have strong mucoadhesive characteristics with the
intestinal mucosa and remain there for extended periods.
   Figures 15 (B) and (C) show GI transit profiles ofthe P(MAA-g-EG) microparticles
containing 1:1 and 1:O molar ratio of MAA/EG The P(MAA-g-EG)(1:O)
microparticles immediately passed through the stomach and the small intestine. In
contrast, the P(MAA-g-EG) microparticles containing 1:1 ratio of MAAIEG remained
in the small intestine for extended period and transited slowly to the large intestine.
These results indicated that the polymer composition as expressed by the molar ratio of
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P(.MAA-g-EG) affected tke GI traksit profile.
   Gl tragsit cftvv'e differept size (SS aRd L size) gf P(MAA-g-EG)(1 : l) microparticles
vv•'as alsc compared iR tkis stsdÅr.', as shovv'# in Fig. I5 (B) aRd (D), respectively. Botk
microparticles passed tkrcugh tke stomach and accumulated iR the small intestine
slcx7vly, aR{il tl:iere are fio sigRificag{ `3ifferekce iR the distribgtioR profiles ef L ak{[l SS
size of P(MAA--g-•EG)( l : l ) micropardcles.
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Table 6.
Recovery O/o ofmicroparticles in the whole GI tract at 1 h following oral administration
Preparation Recovery O/o
P(MAA-g-EG) microparticles
     MAA:EG=1 :O SS size
     MAA:EG==1:1 SS size
     MAA:EG=1:1 L size
Polystyrene microparticles
*[*[ 48.2 Å} 11.5
97.7 Å} 6.4
96.4 Å} 3.4
47.5 Å} 3.6
]**
**
       Each value represents the mean Å} S.E. (n=3)
       Statistically significant difference between the preparation: pÅqO.05,", pÅqO.O 1 , "*
3.2 Transit parameters of microparticles in the GI tract
   Table 7 shows the values of the rate constants obtained by fitting the percentage of
the microparticles remaining versus time profiles to the equations using a non-linear
least square program, MULTI [43]. The gastric and intestinal emptying rate constants
of P(MAA-g-EG)(1:1) were significantly lower than that of polystyrene and
P(MAA-g-EG)(1 :O) microparticles.
    P(MAA-g-EG) microparticles with smaller size had slightly decreased gastric
emptying rate constant. In addition, the intestinal emptying rate constant was
significantly decreased by virtue ofreduction ofthe particle size.
Table 7.
Kinetic parameters (gastric, ki, and intestinal, k2, emptying rate constant) ofmicroparticles in the GI tract
Preparation k, (h-i) k, (h-i)
P(MAA-g-EG) microparticles
     MAA:EG=1 :O SS size
     MAA:EG==1:1 SS size
     MAA:EG=1:1 L size
Polystyrene microparticles
O.94
O.88
O.93
Ll1
1.84
O.46
O.67
1.34
3.3 Mucoadhesion of microparticles in the intestinal tract
   To further understand the mucoadhesive properties of P(MAA-g-EG), the
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mucoadhesion of the particles to the duodenal mucosa was evaluated by in situ closed
loop technique. Table 8 shows the mucoadhesive characteristics of
P(MAA-g-EG)(1:1), P(MAA-g-EG)(1:O) and polystyrene microparticles to the
duodenal mucosa. More than 50 O/o ofthe polystyrene micropanicles were eluted from
the duodenum with the PBS solution, while approximately 70 O/o of the
P(MAA-g-EG)(1:1) microparticles remained in the duodenum after PBS perfusion.
These results indicated that the P(MAA-g-EG)(1:1) microparticles had the strong
mucoadhesive capacities to the intestinal mucosa. In addition, P(MAA-g-EG)(1:1)
remained longer in the duodenum compared with P(MAA-g-EG)(1:O). These results
indicate that the PEG composition as expressed by,the PEG molar ratio of the
P(MAA-g-EG) microparticles strongly affects the mucoadhesive properties, and PEG
chains possibly act as the anchor to the intestinal mucosa.
  In addition, the small size P(MAA-g-EG) microparticles remained more in the
intestinal lumen compared with those of large size. These results suggested that
particle size of P(MAA-g-EG) microparticles influenced their mucoadhesive capacity,
and the smaller particle size of P(MAA-g-EG) exhibited the stronger mucoadhesive
characteristics to the duodenal mucosa.
    Table 8.
    Mucoadhesive properties of P(MAA-g-EG) and polystyrene microparticles in the duodenum.
Preparation Mucoadhesive O/o
P(MAA-g-EG) microparticles
   MAA:EG=1 :O SS size
  MAA:EG=1:1 SS size
  MAA:EG=1:1 L size
Polystyrene microparticles
   56.3 Å}3.6 ],
   70A Å} 2.4*[
   51.6Å}3.2
              *
   43.5 Å} 6.3
Each value represents the mean Å} S.E. (n=3).
Statistically significant difference between the preparation: pÅqO.05,*.
                                55
4. Discussion
   As shown in Chapter 1 and 2, the P(MAA-g-EG) microparticles could enhance
insulin absorption and induce bigger hypoglycemic effect following oral administration.
This absorption enhancement of insulin by the hydrogels may be due to the protection
of insulin from proteolytic degradation by inhibiting proteases [16] and adhesion to the
intestinal mucosa [18,20]. However, the mucoadhesive characteristics ofthe hydrogels
in the GI tract have not been studied. To identify the mucoadhesive characteristics of
P(MAA-g-EG) to the GI tract, in vivo GI transit and in situ mucoadhesion studies were
carried out in this chapter.
   As shown in Fig.15 (B) and (C), the GI transit of P(MAA-g-EG) containing PEG
chains was slower than that of crosslinked PMAA microparticles. Similarly, the
mucoadhesive capacity of P(MAA-g-EG)(1:1) microparticles to the duodenal mucosa
was higher than that of P(MAA-g-EG)(1:O) microparticles (Table 8). These results
imply that the PEG-containing hydrogels exhibit strong mucoadhesive capacities to the
intestinal mucosa. Sahlin et al. reported before that the tethered PEG chains enhanced
adhesion to the mucus layers due to interdiffusion and entanglement with the mucus
layers [19]. Furthermore, Huang et al. [18] showed that the adhesion of
P(MAA-g-EG) containing tethered PEG chains was significantly higher at pH 7.4
compared to pH 3.2, indicating that the increased adhesion of the polymer gel was
primarily due to the interaction between the PEG chains and the mucus and not due to
the hydrogen bonding by the carboxyl groups. From these facts, it was concluded that
tethered PEG chains in the P(MAA-g-EG) microparticles could easily interpenetrate and
entangle with the mucus layers, which prolong the retention to the GI tract.
   Another important factor related to the mucoadhesion is the particle size of the
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hydrogels. Recently, a size-dependent particle deposition in the GI tract of rats has
been suggested [28,29]. The authors reported an increased adherence for smaller
particles in the whole gut. As shown in Figs. 15 (B) and (D), the GI transit profiles of
SS and L size were not significantly different. However, the gastric and intestinal
emptying rate constant of SS size were decreased compared with L size. Similarly, the
particle size of P(MAA-g-EG) microparticles also influenced on the mucoadhesive
capacities to the duodenal mucosa (Table 8). These results imply that mucoadhesive
capacities to the intestinal mucosa was dependent on the particle size, and smaller size
microparticles can easily and deeply interpenetrate into the mucus layers, which show
stronger mucoadhesive capacities to the intestinal mucosa.
   These results demonstrate that there is a good correlation between mucoadhesive
characteristics of P(MAA-g-EG) microparticles and in vivo insulin oral absorption.
As shown in Chapter 2, PEG molar ratio and particle size strongly influenced on the
insulin oral absorption and the smaller ILP size with MAA:EG=1:1 greatly enhanced
insulin oral absorption, achieving a 9.5 O/o pharamacological availability. From the
results in this study, the microparticles ofdiameters ofÅq53 pm (SS size) composed ofa
1:1 molar ratio of MAAIEG show strongest mucoadhesive capacities to the intestinal
mucosa. Generally, insulin degradation by pancreatic proteases, such as trypsin and
alpha-chymotrypsin, occurs in both intestinal fluid and the mucuslglycocalyx layers
[1,2]. Interpenetration ofthe carriers into the mucus layers might lead to a reduction in
proteolytic degradation because insulin is released more closely to the surface of the
intestinal epithelial cells. These imply that the P(MAA-g--EG) (MAA:EG=1:1, SS
size) microparticles can provide near instant insulin release at the absorption site
resulting in a higher local concentration, thereby allowing more insulin absorption.
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5. Conclusions
   In this study, I demonstrated the ability of tethered PEG chains attached to
complexation hydrogels to enhance the retention of the particles in the GI tract.
Furthermore, the particle size of P(MAA-g-EG) also influenced the mucoadhesive
capacities and smaller size microparticles gave higher mucoadhesiveness. These
results indicated that P(MAA-g-EG) microparticles of diameter of Åq53 pm (SS size)
composed of a 1:1 molar ratio of MAAIEG units have the strong mucoadhesive
properties to the GI mucosa. This property of the carriers is highly desired in the oral
delivery applications, since increasing the residence time of therapeutic peptide and
proteins at the targeted site ofabsorption can significantly improve the fraction oforally
administered peptide and protein drugs that reaches the blood circulation.
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Chapter4
Novel mucosal insulin delivery systems based
         on fusogenic liposomes
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1. Introduction
   Fusogenic liposomes (FL) are unique delivery vehicles equipped with the envelope
glycoprotein of Sendai virus (SeV). FL are prepared by fusing conventional liposomes
with inactivated SeV particles, and can deliver encapsulated contents directly and
                       '
efficiently into the cytoplasm through membrane fusion, with the same mechanism as
SeV infection [21-23]. The aim in Chapter 4 was to evaluate the potential of FL to
improve the mucosal absorption of peptide and protein drugs. Although it has been
reported that FL had a wide range of target cells, their applicability to the intestinal
                                             '
membrane have not yet been established. Therefore, I first investigated the infectivity
of SeV to the various intestinal mucosa. The mucuslglycocalyx layers have been
known to envelop the surface of the intestinal epithelium and are regarded as an
undesirable diffusion barrier that impedes access to absorptive cells of macromolecules
and particles [45,46]. As this layer may also impede the accessibility of FL to the
intestinal epithelium, the effect of removing the mucuslglycocalyx layers by
hyaluronidase pretreatment on membrane fusion was examined. Previous in situ
absorption study proved that the mucuslglycocalyx layers were successfu11y diminished
without causing detectable cellular damage by hyaluronidase pretreatment [1,2]. The
absorption of peptide drugs from various intestinal mucosa with the aid of FL was
examined using insulin as a model peptide drug. One of the limiting factors for
improving insulin absorption from the intestinal epithelium may be the degradation of
insulin in the intestinal cytosol by insulin degrading enzyme (IDE) [47,48]. IDE is the
neutral thiol metalloproteinase involved in the intracellular metabolism of insulin in
hepatocytes, adipocytes, kidney, muscle cells, intestinal tissue, and other cells [47-49].
Therefore, I investigated whether the co-administration of IDE inhibitor would further
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increase the absorption enhancement of insulin by the intestinal administration of FL.
Finally, to ensure the safety of FL as an intestinal delivery canier, the intestinal damage
was evaluated by lactate dehydrogenase (LDH) leakage.
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2. Experimental section
2.1. Materials
   Recombinant human insulin (26.0 unitslmg) was the same as described in Materials
of Chapter 2. Lyophilized hyaluronidase (EC 3.2.1.35; Type IV S from bovine testes;
MW==56 KDa, 1370 U!mg solid), sodium taurodeoxycholate, and
p-chloromercuribenzoate (PCMB) were purchased from Sigma-AIdrich Chemical Co.,
Ltd. (St. Louis, MO, USA). Purified Egg Yolk phosphatidylcholine (PC),
L-ct-dimyristoyl phosphatidylglycerol (PG) and cholesterol (Chol) were obtained from
Nippon Oil and Fats Co., Ltd. (Tokyo, Japan). Polycarbonate membranes (pore size
O.2 pm, Anodisc) were obtained from Whatman plc. (Kent, UK). Sendai virus (Z
strain) was prepared in embryonated chicken eggs as described previously [50]. All
other chemicals used were of reagent grade without further purification.
2.2. Fusion study of SeV
   This research complied with the regulations of the Committee on Ethics in the Care
and Use ofLaboratory Animals ofNational Institute ofAdvanced Industrial Science and
Technology, according to the institutional regulations of recombinant DNA experiments.
Expression of the green fluorescent protein (GFP) gene carried by recombinant SeV
(GFP-SeV) was used to probe the SeV infection (e.g., delivery of the viral genome
through membrane fusion), and UV-inactivated virus was used as a negative control.
Male Sprague-Dawley rats (180-220 g) were purchased from Tokyo Laboratory
Amimals Science Co., Ltd. (Tokyo, Japan), Animals were housed in rooms controlled
at 23Å}1 OC and 55Å}5 O/o relative humidity and allowed free access to water and food
during acclimatization, but they were fasted for 24 h before experiments. Following
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anesthetization by the intraperitoneal injection of sodium pentobarbital (50 mglkg;
Dainippon Pharmaceutical Co., Ltd., Osaka, Japan), the rats were restrained in a supine
position on a thermostatically controlled board at 37 OC and maintained body
temperature. The ileum, the colon and the rectum were exposed following a small
midline incision carefu11y made in the abdomen, and each segment was cannnulated at
both ends using polypropylene tubings (4 mm o.d., 2 mm i.d., Saint-Gobain Norton Co.,
Ltd., Nagano, Japan). These were securely ligated to prevent fluid loss and
subsequently, carefully returned to their original location inside the peritoneal cavity.
In order to wash away the intestinal content, phosphate-buffered saline (PBS; pH 7.4) at
37 OC was singly circulated through the cannula at 5 mLlmin for 4 min using a
peristaltic pump (PSK-51, Nikkiso Co., Ltd., Tokyo, Japan). Subsequently, the
intestinal segments were exposed to 1.0 mL of PBS as a control and hyaluronidase
solution dissolved in PBS (1.92Å~105 UlmL) for 30 min. After exposure, the segments
were carefu11y rinsed with 20 mL of PBS at 37 OC and the segments were tightly closed
following the removal of the cannulation tubing. The SeV suspensions were directly
administered to the intestinal segments and the abdomen was sutured. At 16 h
following administration, each segment was removed and tissue specimens were
prepared. The specimens treated with the tissue-embedding medium O.C.T compound
(Tissue-tek@, Sakura Finetek, Inc., Torrance, CA, USA) were frozen in acetone, and 20
pm transverse frozen sections were made in a cryostat (Leica CM 1850, Leica
Microsystems, Co., Ltd., Heidelberg, Germany) at -20 OC. Sections were placed on
slides, and dried at room temperature. To prevent the bleaching of the fiuorescence
during microscopic examination, the sections were mounted in anti-fading reagents
(Aqua-Poly, Polysciences, Inc. Wanington, PA, USA). Expression ofthe GFP induced
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by GFP-SeV was determined by confocal laser scanning microscopy (Radiance 2100,
Bio-Rad Laboratories, Hercules, CA, USA). All photographs were taken with Å~ 100
magnification.
2.3. Preparation and characterization of FL containing insulin
   Multilamellar liposomes were prepared by the freezing-thawing method using 120
mg lipids (PC:PG:Chol=4:1:5 molar ratio). The lipid mixtures were dissolved in a
small amount of benzenelmethanol mixture (95:5, vlvO/o), and the solvent was rotary
evaporated to obtain a thin lipid film. The liposome suspension was prepared by
dispersing the dried lipid film with a given amount of insulin solution (either 10 or 30
mglmL) with or without IDE inhibitor, PCMB (1 mglmL) using a vortex mixer. The
liposomes were frozen rapidly in deep freezer and left to thaw at 37 OC. After 5 cycles
of freezing and thawing, unilamellar liposomes were prepared by extrusion through a
O.2 pm polycarbonate membrane and were separated from unencapsulated drugs by
ultracentrifugation (40,OOO rpm, 90 min). Unilameller FL were prepared as described
elsewhere [21-23]. Briefly, unilamelar liposomes were mixed with SeV and incubated
at 37 OC for 2 h with shaking. FL was separated from free liposomes and SeV by
sucrose density-gradient centrifugation (40,OOO rpm, 90 min). The amount of insulin
and PCMB loaded into liposomes was determined by HPLC as described in Chapter 1.
The encapsulation efficiency of insulin and PCMB into FL was calculated based on the
initial and loading amount of drugs. In this study, 3.3 O/o and 13.0 O/o of insulin and
PCMB in the initial solution was loaded into FL, respectively.
2.4. In situ absorption study
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   This research complied with the regulations of the Committee on Ethics in the Care
and Use of Laboratory Animals of Hoshi University. In situ absorption study was
performed in the same in situ system as described above, but except the hyaluronidase
treatment was omitted. The ileum, the colon, and the rectum were treated with PBS at
37 OC to wash away the intestinal content. Rats were further left on the board at 37OC
for 1 h to be recovered from the elevated blood glucose levels due to the surgical
operations describe above. Following 1 h ofrest, the insulin solution or each liposome
were directly administered into the ileal, the colonic, and the rectal loops. The dose of
all samples was fixed at 5 and 1O IU!kg body weight. During the experiment, a O.2 mL
aliquot of blood was collected from the jugular vein at O, 5, 10, 15, 30, 60, 120, 180,
and 240 min following administration. In order to calculate the efficacy of enteral
insulin administration relative to subcutaneous administration, insulin solutions were
administered subcutaneously. Insulin solution was prepared by dissolving an
appropriate amount of crystalline human insulin in PBS. The insulin subcutaneous
dose was 1 IUIkg body weight. Blood samples (O.2 mL) were collected from the
jugular vein at the injection before, 5, 10, 15, 30, 60, 120, 180, and 240 min following
administration. In order to set the same physical conditions on the rats, the animals
receiving s.c. injection were given the same surgical operation as the in situ absorption
study. The plasma was separated by centrifugation at 13,OOO rpm for 1 min and kept in
a freezer until insulin concentration analysis. The plasma insulin concentrations were
determined on the same day as the absorption study by an immuno-chemiluminometric
assay (MLT research limited, Wales, UK) using a microplate luminometer (Mithras
LB940, Beltold Japan Co., Ltd., Osaka, Japan). Blood glucose levels were determined
using a glucose meter (Novo Assist Plus, Novo Nordisk Pharma Ltd., Tokyo, Japan).
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    The total area under the insuiin concentration curve (AUC) from the time O to 240
min was estimated from the sum of successive trapezoids between each data point.
The bioavailability was calculated relative to the s.c. injection as described above. The
plasma peak level (C.ax) and the time taken to reach the plasma peak level (Tmax) were
determined from the plasma insulin level-time curves. The area above the blood
glucose levels-time curve (AAC) was calculated by a trapezoidal rule. The
pharmacological availability (PA) was calculated relative to the insulin s.c. injection, as
described above.
2.5. Biochemical evaluation of intestinal damage
   The colonic loop from the pretreated segment following the in situ experiments as
describe above was used here. The colonic segment was treated with PBS (20 mL) at
37 OC to wash away the intestinal content. PBS (control), 1 O/o (wlv) sodium
taurodeoxycholate (positive control) or FL was administered to the colon and incubated
in the segments for 2 h. Then, the colonic loop was washed with 1.0 mL ofPBS, and
the intestinal fluid was collected, The concentration of lactate dehydrogenase (LDH)
in the fluid was deterrnined using a LDH-Test Wako (Wako Pure Chemical Industries,
Co., Ltd., Osaka, Japan).
2.6. Statistial analysis
   The results were expressed as the mean Å} S.D. For group comparison, an analysis
ofvariance (ANOVA) with a one-way layout was applied. Significant differences in
the mean values were evaluated using Student's t-test. Differences were considered to
be significant when thep value was less than O.05.
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3. Results
3.1. Fusion of SeV to the various intestinal mucosa
   Figure 16 shows GFP expression in the various intestinal membranes fo11owing the
administration of GFP-SeV or UV-inactivated GFP-SeV. GFP expression was clearly
detected in each mucosal membrane after treatment with GFP-SeV, but not in those
treated with UV-inactivated virus, indicating that the GFP gene was successfu11y
delivered into each mucosal segment through membrane fusion. In addition, the
fusion ability of SeV to the large intestine was higher than that to the small intestine.
In the ileal segments, hyaluronidase pretreatment significantly enhanced the GFP
expression (Figure 16D) compared to those untreated (Figure 16A). whereas it did not
affect the GFP expression in the colon (Figures 16B vs. 16E) and the rectum (Figures
16C vs. 16F). These results suggest that the pre-epithelial mucus!glycocalyx layers
constitute a barrier for the fusion of SeV with the ileal membrane, but not with the
colonic and the rectal membranes.
{A)
(D)
(G}
(B)
(E]•)
(H)
(C)
(F)
{])
Fig.16. GFP expression in the ileal (A, D, G), colonic (B. E, H), and rectal (C. F, I) mucosa treated
with GFP-SeV (A-F) or UV-inactivated GFP-SeV (G-I). Each intestinal segment was pretreated
with PBS (A-C, G-I) and hyaluronidase (D-F). Each picture was taken by Å~ 100 magnification.
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3.2. Intestinal absorption of insulin following in situ administration of
insulin-loaded FL
   Figure 17 shows the time-course of the plasma insulin and blood glucose levels
following in situ administration of insulin-loaded FL at a dose of 10 IUIkg into the
colonic segments. No apparent insulin absorption and hypoglycemic effect was
observed in the insulin solution administration group. Similarly, insulin-loaded
liposomes did not enhance insulin absorption, although a slight hypoglycemic effect
was observed. In contrast, a marked increase in the plasma insulin levels accompanied
by a decrease in the blood glucose levels was observed following the in situ
administration of insulin--loaded FL into the colonic segments.
   Figure 18 shows the insulin absorption following FL administration into the ileal,
the colonic, and the rectal segments. In the ileal segment, no apparent insulin
absorption and hypoglycemic effect was observed following FL administration, while
FL induced the dramatic insulin absorption in the colonic and the rectal segments.
     E                                   'E 130
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Fig.17. Plasma insulin (A) and blood glucose (B) levels versus time profiles following colonic
administration of insulin-loaded FL (10 IUfkg). Each value represents the mean Å} S.D. (n=3-4).
Key: (open circle) insulin solution (control); (closed square) insulin-loaded liposomes; (closed
circle) insulin-loaded FL.
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 Fig.18. Plasma insulin (A) and blood glucose (B) levels versus time profiles following in situ
 administration of insulin-loaded FL (10 IUfkg) into various intestinal regions. Each value
represents the mean Å} S.D. (n=3-4). Key: (open circle) ileum; (closed square) colon; (closed
 circle) rectum.
3.3. Effect of loading amounts on the insulin colonic absorption
   Figure 19 shows the effect of the concentration of insulin encapsulated into the FL
on the insulin absorption from the colonic segments (A) and hypoglycemic effect (B).
The FL loaded with insulin in higher concentration (30 mglmL) showed stronger insulin
absorption enhancement effect than those loaded with insulin in lower concentration (1O
mglmL). These results imply that the average number of insulin molecules
encapsulated in a FL panicle is a key factor determining the efficacy ofinsulin delivery
by FL.
                                          a
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 Fig.19. Effect ofinsulin loading amount into FL on plasma insulin (A) and blood glucose (B) levels.
 Each value represents the mean Å} S.D. (n=3-5). Key: (closed circle) IO mg insulin-loaded FL;
 (open circle) 30 mg insulin-loaded FL.
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3.4. Effect of IDE inhibitor on the insulin absorption enhancement effect by FL
   Figure 20 shows the effect of PCMB co-encapsulated in FL on plasma insulin (A)
and on blood glucose (B) levels following the administration of insulin-loaded FL into
the colonic segments at a dose of 5 IUIkg. When the insulin solution was
co-administered with PCMB, the insulin absorption was not increased. Similarly, both
insulin- and PCMB-loaded simple liposomes did not enhance the colonic absorption of
insulin. These results indicated that PCMB did not show the absorption-enhancing
effect of insulin. In contrast, the FL loaded with both insulin and PCMB together
(insulin- and PCMB-loaded FL) further enhanced insulin absorption as compared with
insulin-loaded FL. These results demonstrated that the intracellular degradation of
insulin by IDE strongly affected the insulin absorption by FL.
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 Fig.20. Effect of intra-colonic administration of insulin- and PCMB-loaded FL (5 IUfkg) on
 plasma insulin (A) and blood glucose (B) levels. Each value represents the mean Å} S.D. (n=3-5).
 Key: (closed square) insulin + PCMB solution (control); (open square) insulin- and PCMB-loaded
 liposomes; (closed circle) insulin-loaded FL; (open circle) insulin- and PCMB-loaded FL.
   Table 9 summarizes the pharmacokinetic parameters of insulin following the colonic
administration of insulin-loaded FL. In this study, the pharmacological availability
and relative bioavailability were calculated based on the s.c. injection of 1.0 IUIkg of
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insulin. Insulin-loaded FL was found'to have higher values of pharmacokinetic
parameters, C.., AUC, PA, and BA, than that of insulin solution and insulin-loaded
liposomes. Furthermore, these parameters were further increased by the addition of
IDE inhibitor into the insulin-loaded FL, and their PA and BA values of insulin were
greatly improved, up to approximately 16 O/o and 8 O/o, respectively.
 Table 9.
 Pharmacokinetic parameters following the colonic administration of insulin + PCMB solution, insulin-
 and PCMB-loaded liposomes, insulin-loaded FL, and insulin- and PCMB-loaded FL
Preparation Cmax(PUfML) Tmax(h) AUC(PU'ML"'h) PA (O/o) BA (O/o)
Insulin + PCMB
  solution
Insulin + PCMB
  liposomes
Insulin FL
Insulin + PCMB FL
 7.0 Å} 4.5
 11.7Å}3.5
33.5 Å} 6.2
** **
 50.2 Å} l1.5
O.3 Å} 02
O.2 Å}O.1
O.2 Å} O.1
O.2 Å} O.O
 4.3 Å} 1.0
 6.4 Å} 3.0
21 .5 Å} 13.5
** **24.7 Å} 4.2
 O.6 Å} 1.1
 O.6 Å} O.9
        *IO.1 Å}5.6
       **
15.7 Å} 7.2
 1 .5 Å} O.4
 2.1 Å}1.0
 7.3 Å} 4.6
** **
 8.4 Å} 1.4
Each data represents the mean Å} S.D. (n=3-5).
C.,,: the plasma peak level; T.,.: the time taken to reach the plasma peak level; AUC: the area under the
curve; BA: Relative bioavailability compared to s.c; PA:Pharmacological availability compared to s.c.
Significant difference from the control: pÅqO.05, *, pÅqO.O1, "".
3.5. Biochemical characterization of the colonic membrane damage following FL
administration
   Table 10 shows the LDH leakage following the 2 h administration of FL to the
colonic region. LDH was negligibly leaked into the colonic segment, which was
similar to the leakage seen in the control group. On the other hand, LDH leakage was
significantly induced by the administration of sodium taurodeoxycholate. These data
suggest that insulin-loaded FL did not induce the intestinal damage, and the
absorption-enhancing effect of insulin-loaded FL was not due to a loss of membranous
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barrier function affected by cellular viability.
 Table 10.
 Lactate dehydrogenase (LDH) leakage following
 taurodeoxycholate (positive control)
PBS(control), FL, and 1.0 O/o (wlv) sodium
Preparation LDH leakage (U)
Control
FL
Sodium taurodeoxycholate
O.40 Å} O.1O
O.39 Å} O.18
5.13 Å} O.46 **
Each value represents the mean Å} S.D. (n=3).
Statistically significant difference from control:pÅqO.O1,**.
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4. Discussion
   The absorption ofpeptide and protein drugs from the intestine is limited because of
enzymatic degradation in the GI tract, high molecular weight and hydrophilicity. For
overcoming these limiting factors, various types of liposomes have been used to
enhance intestinal insulin absorption; however, bioavailability ofthe peptide and protein
drugs observed by liposome administration was insuffricient. In order to improve
mucosal insulin absorption by active targeting and delivery, I evaluated the potential of
FL as a mucosal insulin canier. The FL is a delivery system that can introduce the
encapsulated materials into the living cells directly and efficiently through the
membrane fusion [21-23]. From these characteristics, it would be expected that
insulin loaded into the FL would be directly introduced into the intestinal epithelium,
thereby increasing the intestinal insulin absorption.
   As shown in Fig.16, the SeV can deliver the GFP gene into each mucosal membrane
through membrane fusion. SeV membrane fusion was caused by two envelope
glycoproteins, hemagglutinating and neuraminidase (I-IN) and fusion (F) protein [24].
The HN protein is involved in cell binding through attachnent of the virus envelope to
the cellular receptors containing sialic acid, while the F protein plays a major role in
fusion of the envelope with the cell membrane. Sialic acid, the receptor for SeV, is
present on most cell types, including the apical surface of intestinal membrane.
Therefore, SeV can bind to the sialic acid on the surface of intestinal epithelium and
fuses with the cell membrane.
   The effects of FL on the insulin intestinal absorption was dependent on the site of
the administration (ileum, colon and rectum) (Fig. 18), and was consistent with the
results of a fusion study of SeV to the intestinal mucosa using GFP expression as a
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marker (Fig. 16). As shown in Fig.16, the fusion ability of SeV to the large intestine
was higher than that to the small intestine. In addition, it was found that the
mucus/glycocalyx layers ofthe ileal mucosa affected the membrane fusion of SeV. A
possible explanation of the results may be due to the different activities of proteolytic
enzymes responsible for the degradation of the SeV envelope glycoprotein in the small
and the large intestine. Pancreatic enzyme activities were much stronger in the small
intestine than in the large intestine [33]. It has been shown that peptide and protein
drugs were degraded by pancreatic enzymes such as trypsin and chymotrypsin, which
are believed to reside both in the intestinal fluids and the mucuslglycocalyx layers [51].
Asano et al. reported that the SeV envelope glycoproteins were easily degraded by
pancreatic enzymes, such as trypsin and chymotrypsin, and lost their activities of fusion
to the cell membrane [52]. Therefore, the SeV glycoproteins may be degraded more
readily in the ileal mucuslglyocalyx layers than in the colonic and the rectal
mucuslglycocalyx layers, and this may explain the obvious regional differences in the
insulin absorption by FL.
   It was also demonstrated that the increase of the loading amount of insulin in a
single FL was quite effective for facilitating the insulin absorption from the colon (Fig.
19). Accounting that the total number of the FL particles are smaller in the
high-loading preparation (30 mg!mL insulin) than low-loading preparation (10 mglmL)
because insulin amount administered into the intestine was kept constant in this
experiment, specific absorption of insulin per FL particles are increased over the
difference in the concentration of insulin encapsulated. Based on a kinetic and
quantitative analysis of the SeV fusion to the cell membrane, the number of SeV (or FL)
particles capable of fusing with a single cell was limited by the number of the
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absorption site on the cell surface [53]. Therefore, the fusion of FL to the intestinal
mucosa might be already saturated even at the low concentration ofthe FL. This may
be one ofthe limiting factors for the use ofFL to the mucosal delivery systems.
   Regarding the permeation of insulin into the intestinal epithelium, Bai et al. reported
that insulin was highly degraded by IDE in the intestinal cytoplasm and it potentially
limits the transpepitheilal transport of insulin [47,48]. In this study, it is observed that
in the co-encapsulation of PCMB as the IDE inhibitor further increased FL's
enhancement effect of insulin colonic absorption (Fig. 20). This implies that insulin,
which was directly introduced into the cytosol by the FL membrane fusion, was strongly
degraded by the cytosolic IDE. PCMB, a sulfltydryl-modifying agent, has been used
to inhibit the degradation ofinsulin by IDE in the various tissue cytoplasm [47,48]. In
the present study, no absorption enhancing effect was observed following insulin and
PCMB solution coadministration and the simple liposomes loaded with both insulin and
PCMB together. From these findings, it is suggested that PCMB did not have an
absorption enhancing effect, and further increasing the absorption enhancement of
insulin was only due to reducing the degradation of insulin in the intestinal cytosol.
   Generally, the absorption of insulin from the intestine is limited because of
enzymatic degradation in the gastrointestinal tract and low permeability though the
intestinal mucosa. To date, various strategies have been used to improve intestinal
absorption of insulin, however, mucosal bioavailability of insulin was only improved up
to le-5 O/o by co-administration with absorption enhancers [27] or enzyme inhibitors [27],
and chemical modification [8] in the same in situ loop method used in this study. In
addition, some ofthese approaches exhibited several negative effects such as initation
of the intestinal mucosal membrane and impairment of the membrane barrier. In this
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study, we observed that insulin-loaded FL successfu11y enhanced insulin enteral
absorption, achieving approximately 8 O/o bioavailability (Table 9). The high efficacy
ofFL in mucosal delivery is attributed to the protection ofthe peptides by the liposomes
and the direct introduction of insulin into the intestinal epithelial cells though the
membrane fusion. Insulin loaded into the FL may be protected from the enzymatic
degradation in the gastrointestinal tract. In addition, the direct introduction of insulin
into the epithelial cells by FL may increase the insulin local concentration in the
epithelial cells, and passed though the intestinal membrane without detectable cellular
damage (i.e., the absence of LDH leakage). Therefore, our results indicated that the
direct insulin delivery across the epithelial membrane by FL is essential for improving
the absorption of insulin from the intestine. The high bioavailability of insulin
represents potential for mucosal delivery carrier.
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5. Conclusions
     The present findings suggest that FL enhanced the insulin absorption from the
large intestine without causing detectable mucosal damage. The FL's
absorption-enhancing effect of insulin mucosal absorption showed a site-specificity
because the mucous/glycocalyx layers on the small intestinal mucosa impeded the
accessibility of FL to the intestinal mucosa. The absorption-enhancement effect of
insulin was strongly influenced by the loading amount of insulin into FL. Insulin
absorption was further increased by the co-administration of IDE inhibitor, indicating
that the insulin introduced into the epithelium may be degraded by the IDE present in
the cytoplasm. These results imply that FL can potentially be developed as a carrier
for improving insulin absorption from the large intestine. The FL may offer a novel
mucosal delivery method not only for insulin, but for any kind of macromolecules such
as proteins and gene, as long as they can be encapsulated into the liposomes.
Moreover, it is thought that FL is adapted to the large-scale industrial production [54].
We believe that this technology may lead to the achievement of an ideal delivery system
for macromolecular therapeutic drugs.
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SUMMARY
   The development of oral dosage forms of insulin has been diffricult due to
inactivation of insulin by proteolytic enzymes in the gastrointestinal (GI) tract, mainly
in the stomach and the small intestine, and low insulin permeability through the
intestinal mucosa.
   One of the promising carriers for oral delivery of insulin is complexation polymer
hydrogels composed of crosslinked poly(methacrylic acid) and poly(ethylene glycol).
The complexation polymer hydrogels are multi-functional carriers showing high insulin
incorporation efficiency, a rapid insulin release in the intestine based on their
pH-dependent complexation properties, enzyme-inhibiting effects and mucoadhesive
characteristics. Thus, they are potential carriers for insulin delivery via an oral route.
    Another promising canier is fusogenic liposomes (FL), prepared by fusing
conventional liposomes with Sendai virus (SeV). FL can deliver encapsulated contents
directly and efficiently into the cytoplasm through membrane fusion, with the same
mechanism as SeV infection.
   In this thesis, to identify an optimal oral formulation for clinical use of insulin, the
effect of polymer composition and particle size of insulin loaded polymer (ILP) were
investigated in the in situ and the in vivo experiments. Then, the most promising
formulation was selected and subsequently used for in vivo multiple oral administration
studies using diabetic rats. Furthermore, the potential of the FL to improve the
mucosal absorption ofinsulin from rat intestinal membranes was evaluated in the in situ
absorption method.
   In Chapter 1, insulin absorption from ILPs was studied in the in situ loop system.
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The smaller sized microparticles (SS-ILP) showed a rapid burst-type insulin release and
higher insulin absorption compared with the microparticles having larger sizes, resulting
in greater hypoglycemic effects without detectable mucosal damage. In fact, SS-ILP
demonstrated higher mucoadhesive capacity to the jejunum and the ileum than those of
L-ILP. Moreover, SS-ILP's enhancement effect ofinsulin mucosal absorption showed
a site-specificity, demonstrating maximum effect at the ileal segment. These results
imply that the particle size and delivery site are very important factors for ILP with
respect to increasing the bioavailability ofinsulin following oral administration.
   The in vivo study of insulin oral absorption by ILP was investigated in Chapter 2.
The microparticles of diameters of Åq53 pm (SS-ILP) composed of a 1:1 molar ratio of
methacrylic acidlethylene glycol units showed the most pronounced hypoglycemic
effects following oral administration to healthy rats, achieving a 9.5 O/o pharmacological
availability compared to subcutaneous insulin injection. Their usefulness was also
confirmed with both type 1 and 2 diabetic rats groups. In a multiple administration
study, SS-ILP significantly suppressed the postprandial rise in blood glucose and
showed continuous hypoglycemic effects following 3 timeslday oral administration to
both diabetic rats groups in the presence offoods. These results indicate that the blood
glucose levels of diabetic rats can be effectively controlled by oral SS-ILP
administration, and thus SS-ILP would be promising delivery canier of insulin via the
oral route.
     In Chapter 3, to clarify the absorption enhancement of insulin by the hydrogels,
the GI transit and mucoadhesive characteristics of the hydrogels in the GI tract were
investigated. The complexation polymer hydrogels showed strong mucoadhesive
capacity and significantly prolonged retention in the GI tract. The ethylene glycol
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content and particle size of the hydrogels influenced significantly the GI transit and
mucoadhesive capacities. The microparticles composed of polymers prepared from
1:1 ratio of methacrylic acidlethylene glycol and having diameters of Åq53 pm showed
the strongest mucoadhesive capacity. These results imply that the mucoadhesive
characteristics of the hydrogels significantly contributed to improve oral insulin
absorption.
   In Chapter 4, absorption enhancement effect of FL was evaluated in the in situ loop
system. Insulin-loaded FL successfu11y enhanced the insulin absorption and induced a
significant hypoglycemic effect following the colonic and the rectal administration
without detectable mucosal damage. This enhancing effect of insulin absorption was
further improved by increasing the amount of insulin loaded in the FL and by
co-encapsulating insulin degrading enzyme (IDE) inhibitor. In contrast, the insulin
absorption was not increased by the ileal administration of FL, because the
mucuslglycocalyx layers overlayed on the ileal epithelium impede the fusion of FL to
the intestinal mucosa.
   In conclusion, it is anticipated that SS-ILP and FL are useful carrier for oral insulin
delivery. However, the insulin bioavailability was not sufficient yet compared with
insulin subcutaneous injection. In order to further improve the insulin intestinal
absorption, a combination of other strategies such as permeation enhancer, enzyme
degradation inhibitor, and site-specific delivery system might be usefu1. It is thought
that the design of novel pharmaceutical delivery systems and the clarification of their
characteristics will lead to the development ofeffective multifunctional dosage form for
oral insulin delivery.
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